Nordion Inc. (TSX: NDN) (NYSE: NDZ), a
leading provider of products and services for the prevention, diagnosis
and treatment of disease, today announced an additional randomized,
multi-centre Phase III clinical trial for TheraSphere®, Nordion's yttrium-90 (Y-90) glass microsphere treatment for liver cancer.
The YES-P trial will be focused primarily in Europe, with additional
locations to be identified globally, and is targeting enrolment of
about 350 patients at approximately 24 sites. The trial will further
evaluate the safety and efficacy of TheraSphere® in the treatment of patients with portal vein thrombosis (PVT)
associated with unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
PVT, a complication in which a clot forms in one of the blood vessels
feeding the liver, occurs in approximately 30 to 40% of HCC cases. The
presence of PVT is a contraindication for most embolic therapies, but
TheraSphere® represents a safe alternative.